Spotlight on Gli36-DsRed-R-Luc
Learn more about this cell line in our scientific spotlights:
Glioblastoma (GBM) patients are known to have a poor prognosis and tumor progression with high mortality and a median survival of only 12-15 months. Currently, anti-GBM therapy includes a multi-modality method involving radiotherapies and surgical removal of the tumor in combination with chemotherapy.1